OncoMatch/Clinical Trials/NCT06201247
Off-the-shelf CD123 CAR-NK for R/R AML
Is NCT06201247 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies JD123 for acute myeloid leukemia, in relapse.
Treatment: JD123 — This is a single-centre, single-arm, open-label, first-in-human (FIH) study to evaluate the safety, tolerability and preliminary efficacy of universal Off-the-shelf CAR-NK cells targeted CD123 (JD123 injection) in the treatment of refractory or relapsed CD123-positive acute myeloid leukemia (AML).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: IL3RA overexpression (definitively positive for CD123 by immunohistochemistry or Flow cytometry)
definitively positive for CD123
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic corticosteroids
Exception: inhaled corticosteroids
Systemic use of hormones within 4 weeks prior to enrollment (except for patients with inhaled corticosteroids)
Lab requirements
Kidney function
serum creatinine≤1.5×uln or creatinine clearance rate ≥30ml/min
Liver function
alt≤3×uln, ast≤3×uln, total bilirubin≤2×uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify